Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization

Cancer Genetics and Cytogenetics

Volumn 203, Issue 2, 2010, Pages 193-202

  Lee, Hye Ryun ^a   Oh, Bora ^a   Hong, Dae Sik ^b   Zang, Dae Young ^c   Yoon, Hwi Joong ^d   Kim, Hyeoung Joon ^e   Kim, Inho ^a   Ahn, Jae Sook ^e   Cheong, June Won ^f   Lee, Kyung A ^g   Cho, Kyung Sam ^d   Lee, Mark Hong ^h   Bang, Soo Mee ⁱ   Kim, Tae Young ^a   Yun, Yeo Min ^h   Min, Yoo Hong ^f   Lee, You Kyoung ^b   Lee, Dong Soon ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

^d Kyung Hee University College of Medicine   (South Korea)

^e Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Konkuk University School of Medicine   (South Korea)

ⁱ Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; EARLY GROWTH RESPONSE FACTOR 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

5Q- SYNDROME; ADULT; AGED; ARTICLE; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME G BAND; CHROMOSOME MAP; CONTROLLED STUDY; CYTOGENETICS; ETHNICITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RACE DIFFERENCE; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA AND RINGED SIDEROBLASTS; TRISOMY 8;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES; CHROMOSOMES, HUMAN, PAIR 5; CYTOGENETICS; FEMALE; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KOREA; L-SELECTIN; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTES;

EID: 78650024487     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.007     Document Type: Article

References (32)

1. Brunning R., Porwit A., Orazi A., Baumann I., Germing U., Vardiman J., et al. Myelodysplastic syndromes. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 87-103. IARC, Lyon. S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri, H. Stein (Eds.).
2. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
3. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
4. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008, 87:515-526.
5. Haase D., Germing U., Schanz J., Pfeilstocker M., Nosslinger T., Hildebrandt B., et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007, 110:4385-4395.
6. Giagounidis A.A., Germing U., Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006, 12:5-10.
7. Boultwood J., Fidler C., Strickson A.J., Watkins F., Gama S., Kearney L., et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002, 99:4638-4641.
8. Jaju R.J., Boultwood J., Oliver F.J., Kostrzewa M., Fidler C., Parker N., et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer 1998, 22:251-256.
9. Joslin J.M., Fernald A.A., Tennant T.R., Davis E.M., Kogan S.C., Anastasi J., et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007, 110:719-726.
10. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549-557.
11. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
12. Shaffer L., Tommerup N. ISCN (2005): an international system for human cytogenetic nomenclature 2005, S. Karger, Basel.
13. Germing U., Gattermann N., Strupp C., Aivado M., Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000, 24:983-992.
14. Nosslinger T., Reisner R., Koller E., Gruner H., Tuchler H., Nowotny H., et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001, 98:2935-2941.
15. Lee D.S., Kim S.H., Seo E.J., Park C.J., Chi H.S., Ko E.K., et al. Predominance of trisomy 1q in myelodysplastic syndromes in Korea: is there an ethnic difference? A 3-year multi-center study. Cancer Genet Cytogenet 2002, 132:97-101.
16. Zhao W.L., Xu L., Wu W., Yan H., Tang W., Hu J., et al. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution. Hematol J 2002, 3:137-144.
17. Lee J.H., Shin Y.R., Lee J.S., Kim W.K., Chi H.S., Park C.J., et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003, 17:305-313.
18. Bernasconi P., Klersy C., Boni M., Cavigliano P.M., Calatroni S., Giardini I., et al. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution. Leukemia 2005, 19:1424-1431.
19. Chen B., Zhao W.L., Jin J., Xue Y.Q., Cheng X., Chen X.T., et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005, 19:767-775.
20. Pozdnyakova O., Miron P.M., Tang G., Walter O., Raza A., Woda B., et al. Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the U.S. with a focus on some undefined single chromosomal abnormalities. Cancer 2008, 113:3331-3340.
21. Tasaka T., Tohyama K., Kishimoto M., Ohyashiki K., Mitani K., Hotta T., et al. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan. Leukemia 2008, 22:1874-1881.
22. Lorand-Metze I., Pinheiro M.P., Ribeiro E., de Paula E.V., Metze K. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004, 28:587-594.
23. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
24. Navarro I., Ruiz M.A., Cabello A., Collado R., Ferrer R., Hueso J., et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res 2006, 30:971-977.
25. Irons R.D., Wang X., Gross S.A., Bao L., Ryder J., Chen Y., et al. Prevalence of MDS subtypes in Shanghai, China: a comparison of the World Health Organization and French American British classifications. Leuk Res 2006, 30:769-775.
26. Oguma S., Yoshida Y., Uchino H., Maekawa T., Nomura T., Mizoguchi H. Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res 1995, 19:219-225.
27. Matsushima T., Handa H., Yokohama A., Nagasaki J., Koiso H., Kin Y., et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003, 101:3386-3390.
28. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
29. Lessard M., Helias C., Struski S., Perrusson N., Uettwiller F., Mozziconacci M.J., et al. Fluorescence in situ hybridization analysis of 110 hematopoietic disorders with chromosome 5 abnormalities: do de novo and therapy-related myelodysplastic syndrome-acute myeloid leukemia actually differ?. Cancer Genet Cytogenet 2007, 176:1-21.
30. Pellagatti A., Jadersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007, 104:11406-11411.
31. Slovak M.L., Dewald G.W. International Working Group on MDS cytogenetics: October 2007 meeting report. Leuk Res 2008, 32:1329-1332.
32. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.